Drug Profile
Research programme: metabolic disorder therapeutics - reMYND
Alternative Names: ReS13-I; ReS39-ILatest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator reMYND
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Belgium
- 03 Dec 2020 reMYND plans clinical trials for Type-2 diabetes mellitus programme in mid 2021
- 28 Aug 2020 No recent reports of development identified for preclinical development in Diabetes-mellitus in Belgium